SGHT
Sight Sciences, Inc.
Medical - Devices
Market Cap$232M
5Y Perf.-88.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SGHT vs ABT
Revenue, margins, valuation, and 5-year total return — side by side.
ABT
Abbott Laboratories
Medical - Devices
Market Cap$149.97B
5Y Perf.-28.7%
SGHT vs ABT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SGHT | ABT |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $232M | $149.97B |
| Revenue (TTM) | $80M | $43.84B |
| Net Income (TTM) | $-37M | $13.98B |
| Gross Margin | 86.2% | 54.0% |
| Operating Margin | -44.8% | 17.8% |
| Forward P/E | — | 15.7x |
| Total Debt | $41M | $15.28B |
| Cash & Equiv. | $92M | $7.62B |
SGHT vs ABT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SGHT
ABT
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | 100 | 11.6 | -88.4% |
| Abbott Laboratories (ABT) | 100 | 71.3 | -28.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SGHT vs ABT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABT leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Sight Sciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SGHT
Sight Sciences, Inc.
The Momentum Pick
SGHT is the clearest fit if your priority is momentum.
- +53.0% vs ABT's -33.3%
Best for: momentum
ABT
Abbott Laboratories
The Income Pick
ABT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 11 yrs, beta 0.25, yield 2.5%
- Rev growth 4.6%, EPS growth 133.6%, 3Y rev CAGR -0.9%
- 171.8% 10Y total return vs SGHT's -87.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABT | 4.6% revenue growth vs SGHT's -3.1% |
| Quality / Margins | ABT | 31.9% margin vs SGHT's -46.8% |
| Stability / Safety | ABT | Beta 0.25 vs SGHT's 2.49, lower leverage |
| Dividends | ABT | 2.5% yield; 11-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | SGHT | +53.0% vs ABT's -33.3% |
| Efficiency (ROA) | ABT | 16.6% ROA vs SGHT's -32.2%, ROIC 9.9% vs -274.4% |
SGHT vs ABT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
SGHT vs ABT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLABTLAGGINGSGHT
SGHTSight Sciences, Inc.
1leads
ABTAbbott Laboratories
3leads
6 Total Categories
CATEGORYLEADERvs SGHTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SGHT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ABT7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ABT5/6
Risk & VolatilityBeta, volatility, and downside exposure
ABT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SGHT and ABT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABT is the larger business by revenue, generating $43.8B annually — 551.1x SGHT's $80M. ABT is the more profitable business, keeping 31.9% of every revenue dollar as net income compared to SGHT's -46.8%. On growth, SGHT holds the edge at +12.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| RevenueTrailing 12 months | $80M | $43.8B |
| EBITDAEarnings before interest/tax | -$35M | $10.9B |
| Net IncomeAfter-tax profit | -$37M | $14.0B |
| Free Cash FlowCash after capex | -$25M | $6.9B |
| Gross MarginGross profit ÷ Revenue | +86.2% | +54.0% |
| Operating MarginEBIT ÷ Revenue | -44.8% | +17.8% |
| Net MarginNet income ÷ Revenue | -46.8% | +31.9% |
| FCF MarginFCF ÷ Revenue | -31.9% | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.5% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +14.3% | 0.0% |
Evenly matched — SGHT and ABT each lead in 3 of 6 comparable metrics.
Valuation Metrics
SGHT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| Market CapShares × price | $232M | $150.0B |
| Enterprise ValueMkt cap + debt − cash | $181M | $157.6B |
| Trailing P/EPrice ÷ TTM EPS | -5.81x | 11.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.73x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.38x |
| EV / EBITDAEnterprise value multiple | — | 15.70x |
| Price / SalesMarket cap ÷ Revenue | 3.00x | 3.57x |
| Price / BookPrice ÷ Book value/share | 3.51x | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | 23.61x |
SGHT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ABT leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ABT delivers a 27.3% return on equity — every $100 of shareholder capital generates $27 in annual profit, vs $-59 for SGHT. ABT carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGHT's 0.64x. On the Piotroski fundamental quality scale (0–9), ABT scores 7/9 vs SGHT's 5/9, reflecting strong financial health.
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| ROE (TTM)Return on equity | -59.1% | +27.3% |
| ROA (TTM)Return on assets | -32.2% | +16.6% |
| ROICReturn on invested capital | -2.7% | +9.9% |
| ROCEReturn on capital employed | -32.0% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.64x | 0.32x |
| Net DebtTotal debt minus cash | -$51M | $7.7B |
| Cash & Equiv.Liquid assets | $92M | $7.6B |
| Total DebtShort + long-term debt | $41M | $15.3B |
| Interest CoverageEBIT ÷ Interest expense | -9.29x | 19.22x |
ABT leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ABT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABT five years ago would be worth $8,156 today (with dividends reinvested), compared to $1,284 for SGHT. Over the past 12 months, SGHT leads with a +53.0% total return vs ABT's -33.3%. The 3-year compound annual growth rate (CAGR) favors ABT at -5.7% vs SGHT's -25.8% — a key indicator of consistent wealth creation.
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| YTD ReturnYear-to-date | -42.5% | -29.5% |
| 1-Year ReturnPast 12 months | +53.0% | -33.3% |
| 3-Year ReturnCumulative with dividends | -59.1% | -16.1% |
| 5-Year ReturnCumulative with dividends | -87.2% | -18.4% |
| 10-Year ReturnCumulative with dividends | -87.2% | +171.8% |
| CAGR (3Y)Annualised 3-year return | -25.8% | -5.7% |
ABT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ABT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ABT is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than SGHT's 2.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABT currently trades 62.0% from its 52-week high vs SGHT's 46.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.49x | 0.25x |
| 52-Week HighHighest price in past year | $9.24 | $139.06 |
| 52-Week LowLowest price in past year | $2.74 | $86.15 |
| % of 52W HighCurrent price vs 52-week peak | +46.6% | +62.0% |
| RSI (14)Momentum oscillator 0–100 | 55.0 | 24.2 |
| Avg Volume (50D)Average daily shares traded | 355K | 10.4M |
ABT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SGHT as "Buy" and ABT as "Buy". Consensus price targets imply 124.9% upside for SGHT (target: $10) vs 49.2% for ABT (target: $129). ABT is the only dividend payer here at 2.54% yield — a key consideration for income-focused portfolios.
| Metric | SGHTSight Sciences, I… | ABTAbbott Laboratori… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.67 | $128.71 |
| # AnalystsCovering analysts | 9 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 11 |
| Dividend / ShareAnnual DPS | — | $2.19 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
ABT leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SGHT leads in 1 (Valuation Metrics). 1 tied.
Best OverallAbbott Laboratories (ABT)Leads 3 of 6 categories
Loading custom metrics...
SGHT vs ABT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SGHT or ABT a better buy right now?
For growth investors, Abbott Laboratories (ABT) is the stronger pick with 4.
6% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Abbott Laboratories (ABT) offers the better valuation at 11. 3x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Sight Sciences, Inc. (SGHT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SGHT or ABT?
Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -18.
4%, compared to -87. 2% for Sight Sciences, Inc. (SGHT). Over 10 years, the gap is even starker: ABT returned +171. 8% versus SGHT's -87. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SGHT or ABT?
By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.
25β versus Sight Sciences, Inc. 's 2. 49β — meaning SGHT is approximately 902% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 64% for Sight Sciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SGHT or ABT?
By revenue growth (latest reported year), Abbott Laboratories (ABT) is pulling ahead at 4.
6% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to 28. 2% for Sight Sciences, Inc.. Over a 3-year CAGR, SGHT leads at 2. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SGHT or ABT?
Abbott Laboratories (ABT) is the more profitable company, earning 31.
9% net margin versus -49. 7% for Sight Sciences, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -48. 0% for SGHT. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SGHT or ABT more undervalued right now?
Analyst consensus price targets imply the most upside for SGHT: 124.
9% to $9. 67.
07Which pays a better dividend — SGHT or ABT?
In this comparison, ABT (2.
5% yield) pays a dividend. SGHT does not pay a meaningful dividend and should not be held primarily for income.
08Is SGHT or ABT better for a retirement portfolio?
For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
25), 2. 5% yield, +171. 8% 10Y return). Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +171. 8%, SGHT: -87. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SGHT and ABT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SGHT is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while SGHT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SGHT: 12.5% · ABT: 6.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.